77 results on '"RUA‐FIGUEROA, I."'
Search Results
52. PS3:46 Relationship between damage clustering and mortality in juvenile systemic lupus erythematosus: cluster analyses in a large cohort from the spanish society of rheumatology lupus registry
- Author
-
Torrente-Segarra, V, primary, Salman-Monte, TC, additional, Rua-Figueroa, I, additional, Calvo-Alén, J, additional, López-Longo, FJ, additional, Galindo, M, additional, Olivé, A, additional, and Pego-Reigosa, JM, additional
- Published
- 2018
- Full Text
- View/download PDF
53. VALIDATION ANALYSIS OF THE PHYSICIAN GLOBAL ASSESSMENT (PGA) SCALE IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS INCLUDED IN RELESSER-PROS REGISTRY.
- Author
-
Martín, L. Cáceres, Rua-Figueroa, I., Jiménez, N., Galindo-Izquierdo, M., Calvo-Alen, J., Menor-Almagro, R., Fernandez-Nebro, A., Martínez-Barrio, J., Almaraz, E. Rodríguez, Isacelaya, E. Uriarte, Aurrecoechea, E., Mena-Vázquez, N., Senabre-Gallego, J. M., Bernal, J. A., Gómez, A. Pérez, Torrente, V., Narváez, J., Sanguesa, C., Arévalo, M., and González, M. Freire
- Published
- 2023
- Full Text
- View/download PDF
54. CLINICAL SIGNIFICANCE OF ANTI-LA ANTIBODIES IN SYSTEMIC LUPUS ERYTHEMATOSUS.
- Author
-
Sanguesa, C., Olive, A., Rua-Figueroa, I., Jiménez, N., Galindo-Izquierdo, M., Calvo-Alen, J., Menor-Almagro, R., Fernandez-Nebro, A., Uriarte Isacelaya, E., Aurrecoechea, E., Mena-Vázquez, N., Senabre-Gallego, J. M., Narváez, J., Pérez Gómez, A., Andreu, J. L., Tomero Muriel, E., Bonilla, G., Cobo-Ibáñez, T., Moriano, C., and Garcia Villanueva, M. J.
- Published
- 2023
- Full Text
- View/download PDF
55. COMORBIDITY CLUSTERS AND THEIR RELATIONSHIP WITH SEVERITY AND OUTCOMES OF THE INDEX DISEASES, IN A LARGE MULTICENTER SYSTEMIC LUPUS ERYTHEMATOSUS COHORT (RELESSER REGISTER).
- Author
-
Rua-Figueroa, I., Pérez-Veiga, N., Galindo-Izquierdo, M., Rodríguez Almaraz, E., Erausquin, M. C., Fernandez-Nebro, A., Uriarte Isacelaya, E., Serrano-Benavente, B., Calvo, J., Manrique Arija, S., Senabre-Gallego, J. M., Bernal, J. A., Narváez, J., Tomero Muriel, E., Aurrecoechea, E., Ibañez Barceló, M., Torrente Segarra, V., Sanguesa, C., Freire González, M., and Garcia Villanueva, M. J.
- Published
- 2023
- Full Text
- View/download PDF
56. FIBROMYALGIA AND GLUCOCORTICOIDS USE DRIVES SELF-PERCEIVED DEPRESSION IN SYSTEMIC LUPUS ERYTHEMATOSUS: INSIGHTS FROM A LARGE PROSPECTIVE AND MULTICENTER STUDY USING RELESSER-PROS REGISTER'S DATABASE.
- Author
-
Rua-Figueroa, I., Martínez-Barrio, J., Jiménez, N., Galindo-Izquierdo, M., Isacelaya, E. Uriarte, Fernandez-Nebro, A., Calvo, J., Arija, S. Manrique, Rosas, J., Caño-Alameda, R., Narváez, J., Ros, I., Aurrecoechea, E., Segarra, V. Torrente, Sanguesa, C., González, M. Freire, Muriel, E. Tomero, Horcada, L., Moriano, C., and Moreno, M.
- Published
- 2023
- Full Text
- View/download PDF
57. CHANGES IN THE CAUSES AND PREDICTORS OF LUPUS MORTALITY IN SPAIN THROUGH THE LAST DECADES: DATA FROM THE RELESSER REGISTRY.
- Author
-
Moriano, C., Calvo-Alén, J., Rua-Figueroa, I., Diez Álvarez, E., Bermúdez, C., Martínez-Barrio, J., Galindo-Izquierdo, M., Olive, A., Tomero Muriel, E., Fernandez-Nebro, A., Freire González, M., Fernandez Berrizbeitia, O. B., Pérez Gómez, A., Uriarte Isacelaya, E., Fernandez Cid, C. Marras, Montilla-Morales, C. A., Santos Soler, G., Blanco, R., Rodíguez-Gómez, M., and Vela Casasempere, P.
- Published
- 2023
- Full Text
- View/download PDF
58. OP0042 Bacteremia in systemic lupus erythematosus patients from relesser registry: risk factors, clinical and microbiological characteristics and outcomes
- Author
-
Rua-Figueroa, I, primary, Lόpez-Longo, J, additional, Galindo-Izquierdo, M, additional, Campo, V Del, additional, Cisneros, J De la Torre, additional, Uriarte, E, additional, Vela, P, additional, Tomero, E, additional, and Pego-Reigosa, J, additional
- Published
- 2017
- Full Text
- View/download PDF
59. Efficacy of Raynaud's phenomenon and digital ulcer pharmacological treatment in systemic sclerosis patients: a systematic literature review
- Author
-
Lefebvre, PGD, Nishishinya, MB, Pereda, CA, Loza, E, Giraldo, WAS, Ivorra, JAR, Carreira, P, Rua-Figueroa, I, Pego-Reigosa, JM, and Munoz-Fernandez, S
- Subjects
Raynaud's phenomenon ,Ulcers ,Therapy effectiveness ,Systematic review ,Systemic sclerosis - Abstract
To evaluate the efficacy of current treatments for the Raynaud phenomenon (RP) in patients with systemic sclerosis (SSc), a systematic literature search was performed using Medline, EMBASE, and Cochrane Central Register of Controlled Trials (from 1961 to October 2011). We included meta-analyses, systematic reviews, clinical trials, and high-quality cohort studies published in English or Spanish. Patient populations had to include adults diagnosed with limited cutaneous or diffuse SSc who had associated RP and/or digital ulcers under pharmacological treatment. Efficacy of treatments was evaluated based on: number of RP episodes, RP severity, episode-free time, ulcer improvement/healing, and appearance of new ulcers. We used the Jadad scale of methodological quality to evaluate the quality of randomized clinical trials, and the 2009 Oxford Centre for Evidence-Based Medicine classification for other studies. Of a total of 1617 studies identified, only 27 fulfilled inclusion criteria. Drugs received the following grade recommendations: Grade A for nifedipine, nicardipine, quinapril, IV iloprost, bosentan, tadalafil, and MQx-503; Grade B for beraprost, cicaprost, DMSO, cyclofenil, and atorvastatin; and Grade C for misoprostol, prazosin, OPC-2826, enalapril, sildenafil, antioxidant, and stanazolol. Calcium channel blockers, prostanoids, tadalafil, and bosentan received the highest recommendation level for their effectiveness. However, most systematic reviews reviewed just a handful of studies with small sample sizes and short follow-ups. Our review shows that the existing evidence on the efficacy of RP treatment in SSc patients is inconclusive which calls for further research, especially in the form of prospective studies of high quality with long-term follow-ups.
- Published
- 2015
60. MULTICENTRIC SPANISH ANALYSIS OF EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS PATIENTS TREATED WITH MEPOLIZUMAB.
- Author
-
Rubiño, F., Garcia-Vicuna, R., Vicente-Rabaneda, E. F., Rodríguez Almaraz, E., Lozano Rivas, N., Freire González, M., Olive, A., Nack, A., Narváez, J., Moya, P., Uriarte Isacelaya, E., Alcorta Lorenzo, N., Marenco, J. L., Ramos Giráldez, C., Pinillos, V., Blanco, R., Benavides-Villanueva, F., Martínez-Vidal, M. P., and Rua-Figueroa, I.
- Published
- 2023
- Full Text
- View/download PDF
61. Fibromyalgia in patients with rheumatoid arthritis is associated with higher scores of disability
- Author
-
Naranjo, A, Ojeda, S, Francisco, F, Erausquin, C, Rua-Figueroa, I, and Rodriguez-Lozano, C
- Subjects
Fibromyalgia -- Case studies -- Complications and side effects -- Research ,Disability evaluation -- Research -- Case studies ,Rheumatoid arthritis -- Research -- Complications and side effects -- Case studies ,Health - Abstract
Ann Rheum Dis 2002;660:659 Rheumatoid arthritis (RA) is a chronic polyarticular disease characterised by pain in peripheral joints accompanied by swelling, stiffness, and functional impairment. In some cases it is [...]
- Published
- 2002
62. Factors involved in the progress of preclinical atherosclerosis associated with systemic lupus erythematosus: a 2-year longitudinal study
- Author
-
Rua-Figueroa, I, primary, Arencibia-Mireles, O, additional, Elvira, M, additional, Erausquin, C, additional, Ojeda, S, additional, Francisco, F, additional, Naranjo, A, additional, Rodríguez-Gallego, C, additional, Garcia-Laorden, I, additional, Rodríguez-Perez, J, additional, and Rodríguez-Lozano, C, additional
- Published
- 2009
- Full Text
- View/download PDF
63. FRI0088 Poly(adp-ribose) polymerase (parp) polymorphism in spanish systemic lupus erythematosus (sle) patients
- Author
-
Martin-Donaire, T, primary, Citores, MJ, additional, Rosado-Garcia, S, additional, Rua-Figueroa, I, additional, Garcia-Laorden, I, additional, Rodriguez-Lozano, C, additional, Perez-Aciego, P, additional, Rodriguez-Gallego, C, additional, and Durantez, A, additional
- Published
- 2001
- Full Text
- View/download PDF
64. FRI0089 Il10G promoter polymorphism of the interleukin 10 (il10) in spanish systemic lupus erythematosus (sle) patients
- Author
-
Rosado-Garcia, S, primary, Citores, MJ, additional, Martin-Donaire, T, additional, Rua-Figueroa, I, additional, Garcia-Laorden, I, additional, Rodriguez-Lozano, C, additional, Perez-Aciego, P, additional, Rodriguez-Gallego, C, additional, and Durantez, A, additional
- Published
- 2001
- Full Text
- View/download PDF
65. Disseminated gonococcal infection in an elderly patient.
- Author
-
Rua Figueroa, I, primary, Loza Cortina, E, additional, Gonzalez Suarez, S, additional, Arruabarrena, C E, additional, and Pena Sagredo, J L, additional
- Published
- 1993
- Full Text
- View/download PDF
66. Characterization of Patients With Lupus Nephritis Included in a Large Cohort From the Spanish Society of Rheumatology Registry of Patients With Systemic Lupus Erythematosus (RELESSER)
- Author
-
Galindo-Izquierdo, M, Rodriguez-Almaraz, E, Pego-Reigosa, J, Lopez-Longo, F, Calvo-Alen, J, Olive, A, Fernandez-Nebro, A, Martinez-Taboada, V, Vela C, Freire, M, Narvaez, F, Rosas, J, Ibanez-Barcelo, M, Uriarte, E, Tomero, E, Zea, A, Horcada, L, Torrente, V, Castellvi, I, Calvet, J, Menor-Almagro, R, Aguirre Zamorano, M, Raya, E, Diez-Alvarez, E, Vazquez-Rodriguez, T, Garcia de la Pena, P, Movasat, A, Andreu, J, Richi, P, Marras, C, Montilla-Morales, C, Hernandez-Cruz, B, Marenco de la Fuente, J, Gantes, M, Ucar, E, Alegre-Sancho, J, Manero, J, Ibanez-Ruan, J, Rodriguez-Gomez, M, Quevedo, V, Hernandez-Beriain, J, Silva-Fernandez, L, Alonso, F, Perez, S, Rua-Figueroa, I, RELESSER Grp, Spanish Soc Rheumatology Systemic, Universitat de Barcelona, Universidad de Cantabria, The RELESSER Group, from the Spanish Society of Rheumatology Systemic Autoimmune Diseases Study Group (EASSER), [Galindo-Izquierdo,M, Rodriguez-Almaraz,E] Rheumatology Department, Hospital 12 Octubre, Madrid. [Pego-Reigosa,JM] Rheumatology, University Hospital Complex, Instituto de Investigación Biomédica, Vigo, Spain. [López-Longo,FJ] Rheumatology Department, Gregorio Marañón University Hospital, Madrid. [Calvo-Alén,J] Rheumatology Department, Sierrallana Hospital, Torrelavega. [Olivé,A] Rheumatology Department, Germans Trías i Pujol University Hospital, Badalona. [Fernández-Nebro,A] Rheumatology Department, Hospital Regional Universitario de Málaga, Málaga. [Martinez-Taboada,V] Rheumatology Department, Marques de Valdecilla Hospital, Santander. [Vela-Casasempere,P] Rheumatology Department, Hospital General de Alicante, Alicante. [Freire,M] Rheumatology Department, Hospital Universitario Juan Canalejo, Coruña. [Narvaez,FJ] Rheumatology Department, Hospital Universitario de Bellvitge, Barcelona. [Rosas,J] Rheumatology Department, Hospital Marina Baixa, Villajoyosa. [Ibáñez-Barceló,M] Rheumatology Department, Hospital Son Llatzer, Palma de Mallorca. [Uriarte,E] Rheumatology Department, Hospital de Donosti, San Sebastián. [Tomero,E] Rheumatology Department, Hospital Universitario de La Princesa. [Zea,A] Rheumatology Department, Hospital Universitario Ramón y Cajal, Madrid. [Horcada,L] Rheumatology Department, Complejo Hospitalario de Navarra, Pamplona. [Torrente,V] Rheumatology Department, Hospital Moisés Broggi. [Castellvi,I] Rheumatology Department, Hospital de la Santa Creu i Sant Pau, Barcelona. [Calvet,J] Rheumatology Department, Hospital Parc Taulí. Sabadell. [Menor-Almagro,R] Rheumatology Department, Hospital de Jerez, Jerez de la Frontera. [Aguirre Zamorano,MA] Rheumatology Department, IMIBIC-Reina Sofia Hospital, Cordoba. [Raya,E] Rheumatology Department, University Hospital San Cecilio, Granada. [Díez-Álvarez,E] Rheumatology Department, Leon Hospital, Leon. [Vázquez-Rodríguez,T] Rheumatology Department, Hospital Lucus Augusti, Lugo. [García de la Peña,P] Rheumatology Department, Hospital Norte Sanchinarro, Madrid. [Movasat,A] Rheumatology Department, Hospital Universitario Príncipe de Asturias, Alcalá de Henares. [Andreu,JL] Rheumatology Department, Hospital Puerta de Hierro, Majadahonda, Madrid, [Richi,P] Rheumatology Department , Hospital Infanta Sofía, San Sebastián de los Reyes, Madrid. [Marras,C] Rheumatology Department , Hospital Virgen de la Arrixaca, Murcia, Spain. [Montilla-Morales,C] Rheumatology Department , Hospital Clínico Universitario de Salamanca, Salamanca. [Hernández-Cruz,B] Rheumatology Department , University Hospital Virgen Macarena. [Marengo de la Fuente,JL] Rheumatology Department , Hospital de Valme, Sevilla. [Gantes,M] Rheumatology Department, Hospital Universitario de Canarias, Tenerife. [Úcar,E] Rheumatology Department, Hospital de Basurto, Bilbao. [Alegre-Sancho,JJ] Rheumatology Department , Hospital Universitario Dr Peset, Valencia. [Manero,J] Rheumatology Department, Hospital Miguel Servet Zaragoza. [Ibáñez-Ruán,J] Rheumatology Department , Clínica POVISA, Vigo. [Rodríguez-Gómez,M] Rheumatology Department , Complejo Hospitalario Universitario de Ourense, Ourense. [Quevedo,V] Rheumatology Department, Hospital de Monforte, Lugo. [Hernández-Beriaín,J] Rheumatology Department, Hospital Insular de Gran Canaria, Las Palmas de Gran Canaria. [Silva-Fernández,L] Rheumatology Department, Hospital Universitario de Guadalajara, Guadalajara. [Alonso,F, Pérez,S] Statistical Department, Research Unit, Spanish Society of Rheumatology (SER), Madrid. [Rúa-Figueroa,I] Rheumatology Department, Doctor Negrín University Hospital, Gran Canaria, Spain., and This work was supported by the Spanish Society of Rheumatology, FIS/ISCIII (grant number PI11/02857), GSK, Roche, Novartis, and UCB.
- Subjects
Diseases::Pathological Conditions, Signs and Symptoms::Pathologic Processes::Disease Attributes::Recurrence [Medical Subject Headings] ,Male ,reumatología ,sistema de registros ,Diseases::Immune System Diseases::Autoimmune Diseases::Lupus Erythematosus, Systemic::Lupus Nephritis [Medical Subject Headings] ,humanos ,España ,Lupus nephritis ,adolescente ,030204 cardiovascular system & hematology ,Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humans [Medical Subject Headings] ,0302 clinical medicine ,Recurrence ,Nefritis lúpica ,Medicine ,Registries ,Geographicals::Geographic Locations::Europe::Spain [Medical Subject Headings] ,Systemic lupus erythematosus ,nefritis lúpica ,Reumatologia ,General Medicine ,adulto ,Reumatología ,Lupus Nephritis ,3. Good health ,adulto joven ,Nephrology ,Named Groups::Persons::Age Groups::Adolescent [Medical Subject Headings] ,Cohort ,ComputingMethodologies_DOCUMENTANDTEXTPROCESSING ,Female ,Research Article ,Adult ,medicine.medical_specialty ,Health Care::Health Care Quality, Access, and Evaluation::Quality of Health Care::Health Care Evaluation Mechanisms::Epidemiologic Study Characteristics as Topic::Epidemiologic Studies::Cohort Studies::Retrospective Studies [Medical Subject Headings] ,Adolescent ,Sistema de registro ,Recurrencia ,Observational Study ,Check Tags::Male [Medical Subject Headings] ,Lupus ,Lower risk ,Nefrologia ,03 medical and health sciences ,Estudios retrospectivos ,Young Adult ,Rheumatology ,Internal medicine ,Named Groups::Persons::Age Groups::Adult [Medical Subject Headings] ,Humans ,Risk factor ,Espanya ,Retrospective Studies ,030203 arthritis & rheumatology ,business.industry ,estudios retrospectivos ,Retrospective cohort study ,Odds ratio ,medicine.disease ,Surgery ,Health Care::Health Care Quality, Access, and Evaluation::Quality of Health Care::Health Care Evaluation Mechanisms::Data Collection::Records as Topic::Registries [Medical Subject Headings] ,Transplantation ,Check Tags::Female [Medical Subject Headings] ,Spain ,Disciplines and Occupations::Health Occupations::Medicine::Internal Medicine::Rheumatology [Medical Subject Headings] ,business ,recurrencia - Abstract
Supplemental Digital Content is available in the text, The aim of the study was to profile those patients included in the RELESSER registry with histologically proven renal involvement in order to better understand the current state of lupus nephritis (LN) in Spain. RELESSER-TRANS is a multicenter cross-sectional registry with an analytical component. Information was collected from the medical records of patients with systemic lupus erythematosus who were followed at participating rheumatology units. A total of 359 variables including demographic data, clinical manifestations, disease activity, severity, comorbidities, LN outcome, treatments, and mortality were recorded. Only patients with a histological confirmation of LN were included. We performed a descriptive analysis, chi-square or Student's t tests according to the type of variable and its relationship with LN. Odds ratio and confidence intervals were calculated by using simple logistic regression. LN was histologically confirmed in 1092/3575 patients (30.5%). Most patients were female (85.7%), Caucasian (90.2%), and the mean age at LN diagnosis was 28.4 ± 12.7 years. The risk for LN development was higher in men (M/F:47.85/30.91%, P
67. CD154 microsatellite in rheumatoid arthritis (ra) patients from Canary Islands
- Author
-
Rua-Figueroa, I., Martin-Donaire, T., Losada-Fernandez, I., Rosado, S., Garcia-Laorden, M. I., Erausquin, C., Francisco, F., Ojeda, S., Rodriguez-Gallego, C., Vargas, J. A., Citores, M. J., Perez-Aciego, P. A., and Naranjo, A.
68. Diffuse alveolar hemorrhage in patients with systemic lupus erythematosus: data from the Spanish society of rheumathology Lupus Register (RELESSER).
- Author
-
Garcia-Villanueva MJ, Garrote-Corral S, Pego-Reigosa JM, Jiménez Otero N, Uriarte Isazelaia E, Olivé Marqué A, Sangüesa Gómez C, Freire González M, Aurrecoechea Aguinaga E, Raya Álvarez E, Tomero Muriel E, Montilla Morales C, Galindo Izquierdo M, Calvo-Alén J, Menor-Almagro R, Serrano Benavente B, Martinez-Barrio J, Hernández-Beriain JA, Ibañez Barceló M, Bonilla Hernan G, Rosas J, Salgado Pérez E, Fernández-Nebro A, and Rua-Figueroa I
- Abstract
Introduction: Diffuse alveolar hemorrhage (DAH) is a rare complication with high mortality in patients with systemic lupus erythematosus (SLE). Early diagnosis and treatment are essential to improve patient prognosis. To determine the characteristics of patients with DAH and their mortality in a Spanish cohort of patients with SLE., Methods: Patients from the RELESSER (Spanish Society of Rheumatology Lupus Register) who had had at least one confirmed episode of DAH were included. Epidemiological, clinical, and laboratory characteristics were analyzed., Results: 4024 patients were included in the RELESSER register, 37 (0.9%), had at least one recorded episode of DAH. Only further data for 14 patients could be analyzed. In total, 92.9% were women, and for 4 (28.6%) DAH coincided with the debut of SLE. More than 80% of patients had renal involvement and thrombocytopenia. The most frequent manifestations were dyspnea (85.7%) and hypoxemia (100%), with the classic triad of hemoptysis, anemia and pulmonary infiltrates, appearing in 6 (46.2%) patients. The most frequently used treatments were glucocorticoids (85.7%) and cyclophosphamide (69.2%); plasmapheresis was utilized in 5 patients (35.7%) and 8, (57.1%) received intravenous immunoglobulins; 12 (85.7%) patients required admission to the ICU and 5 (35.7%) died. Tobacco use, history of lupus nephritis (LN), concomitant infection, and treatment with cyclophosphamide were more frequent in patients who died., Conclusions: DAH is rare in patients with SLE; in up to one-third of patients, it may appear at the onset of the disease. Some factors, such as smoking, a history of LN, treatment with cyclophosphamide, or concomitant infection, are more prevalent in patients with an unfavorable outcome., (© 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.)
- Published
- 2024
- Full Text
- View/download PDF
69. Damage in a large systemic lupus erythematosus cohort from the Spanish Society of Rheumatology Lupus Registry (RELESSER) with emphasis on the cardiovascular system: a longitudinal analysis.
- Author
-
Altabás-González I, Rua-Figueroa I, Mouriño C, Roberts K, Jimenez N, Martinez-Barrio J, Galindo M, Calvo Alén J, Pérez VDC, Uriarte Itzazelaia E, Tomero E, Freire-González M, Martínez Taboada V, Salgado E, Vela P, Fernandez-Nebro A, Olivé A, Narváez J, Menor-Almagro R, Soler GS, Hernández-Beriain JÁ, Manero J, Aurrecoechea E, Ibarguengoitia-Barrena O, Montilla C, Bonilla G, Torrente-Segarra V, Cacheda AP, García-Villanueva MJ, Moriano-Morales C, Manteca CF, Lozano-Rivas N, Bohórquez C, and Pego-Reigosa JM
- Subjects
- Humans, Longitudinal Studies, Male, Female, Adult, Spain epidemiology, Middle Aged, Cardiovascular Diseases epidemiology, Severity of Illness Index, Disease Progression, Rheumatology, Lupus Erythematosus, Systemic complications, Lupus Erythematosus, Systemic epidemiology, Registries, Cardiovascular System physiopathology
- Abstract
Objective: To assess organ damage, with emphasis on the cardiovascular system, over the different stages of the disease in a large SLE cohort., Methods: Multicentre, longitudinal study of a cohort of 4219 patients with SLE enrolled in the Spanish Society of Rheumatology Lupus Registry. Organ damage was ascertained using the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index (SDI). We longitudinally analysed SDI (globally and for each domain) over time only in the 1274 patients whose dates of damage events had been recorded., Results: During the first year after diagnosis of SLE, 20% of the 1274 patients presented with new damage manifestations. At years 2 and 3, new damage was recorded in 11% and 9% of patients. The annual percentage of patients with new damage after year 5 decreased to 5%. In the first year with the disease, most damage was accumulated in the musculoskeletal, neuropsychiatric and renal systems; in later stages, most damage was in the musculoskeletal, ocular and cardiovascular systems. Considering 'cerebrovascular accident' and 'claudication for 6 months' as cardiovascular items, the cardiovascular system was the second most affected system during the early stages of SLE, with 19% of the patients who presented with damage affected at first year after diagnosis. During the late stages, 20-25% of the patients presenting with new damage did so in this modified cardiovascular domain of the SDI., Conclusions: New damage occurs mainly during the first year following diagnosis of SLE. Cardiovascular damage is relevant in both the early and the late stages of the disease. Strategies to prevent cardiovascular damage should be implemented early after diagnosis of SLE., Competing Interests: Competing interests: None declared., (© Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY. Published by BMJ.)
- Published
- 2024
- Full Text
- View/download PDF
70. Can the Dose of Belimumab be Reduced in Patients with Systemic Lupus Erythematosus?
- Author
-
Rua-Figueroa I, Altabás-González I, Mouriño C, Roberts K, Hernández-Martín A, Casafont-Solé I, Font-Urgelles J, Román-Ivorra JA, Navarro MR, Galindo-Izquierdo M, Salman-Monte TC, Narváez J, Vidal-Montal P, García-Villanueva MJ, Garrote-Corral S, Blazquez-Canamero MA, Fernandez-Cid CM, Piqueras-García M, Martínez-Barrio J, Sánchez-Lucas M, Cortés-Hernández J, Penzo E, Calvo J, de Dios JR, Alvarez-Rodríguez B, Vasques-Rocha M, Tomero E, Menor-Almagro R, Gandía M, Gómez-Puerta JA, Frade-Sosa B, Ramos-Giráldez C, Trapero-Pérez C, Diez E, Moriano C, Muñoz-Jiménez A, and Pego-Reigosa JM
- Abstract
Objectives: The aims of this study were to investigate the prevalence of dose reduction in patients with SLE treated with belimumab (BEL) in Spain, analyze treatment modalities, and determine impact on control of disease activity., Methods: Retrospective longitudinal and multicentre study of SLE patients treated with BEL. Data on disease activity, treatments and outcomes were recorded before and after reduction (6-12 months), and they were compared., Results: A total of 324 patients were included. The dose was reduced in 29 patients (8.9%). The dosing interval was increased in 9 patients receiving subcutaneous BEL and in 6 patients receiving intravenous BEL. The dose per administration was reduced in 16 patients.Pre-reduction status was remission (2021 DORIS) in 15/26 patients (57.7%) and LLDAS in 23/26 patients (88.5%). After reduction, 2/24 patients (8.3%) and 3/22 patients (13.6%) lost remission at 6 months and 12 months, respectively (not statistically significant [NS]). As for LLDAS, 2/23 patients (8.7%) and 2/21 patients (9.5%) lost their status at 6 and 12 months, respectively (NS). Significantly fewer patients were taking glucocorticoids (GCs) at their 12-month visit, although the median dose of GCs was higher at the 12-month visit (5 [0.62-8.75] vs 2.5 [0-5] at baseline)., Conclusion: Doses of BEL can be reduced with no relevant changes in disease activity-at least in the short term-in a significant percentage of patients, and most maintain the reduced dose. However, increased clinical or serologic activity may be observed in some patients. Consequently, tighter post-reduction follow-up is advisable., (© The Author(s) 2024. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For permissions, please email: journals.permissions@oup.com.)
- Published
- 2024
- Full Text
- View/download PDF
71. SLESIS-R: an improved score for prediction of serious infection in patients with systemic lupus erythematosus based on the RELESSER prospective cohort.
- Author
-
Rua-Figueroa I, García de Yébenes MJ, Martinez-Barrio J, Galindo Izquierdo M, Calvo Alén J, Fernandez-Nebro A, Menor-Almagro R, Carmona L, Tejera Segura B, Tomero E, Freire-González M, Sangüesa C, Horcada L, Blanco R, Uriarte Itzazelaia E, Narváez J, Rosas Gómez de Salazar JC, Gómez-Sabater S, Morales CM, Andreu JL, Segarra VT, Aurrecoechea E, Perez A, Nóvoa Medina J, Salgado E, Lozano-Rivas N, Montilla C, Ruiz-Lucea E, Arevalo M, Iñiguez C, García-Villanueva MJ, Exposito L, Ibáñez-Barceló M, Bonilla G, Carrión-Barberà I, Erausquin C, Fragio Gil JJ, Pecondón A, Toyos FJ, Cobo T, Muñoz-Jiménez A, Oller J, Nolla JM, and Pego-Reigosa JM
- Subjects
- Humans, Female, Adult, Middle Aged, Male, Prospective Studies, Immunosuppressive Agents, Logistic Models, Lupus Erythematosus, Systemic complications
- Abstract
Objective: To develop an improved score for prediction of severe infection in patients with systemic lupus erythematosus (SLE), namely, the SLE Severe Infection Score-Revised (SLESIS-R) and to validate it in a large multicentre lupus cohort., Methods: We used data from the prospective phase of RELESSER (RELESSER-PROS), the SLE register of the Spanish Society of Rheumatology. A multivariable logistic model was constructed taking into account the variables already forming the SLESIS score, plus all other potential predictors identified in a literature review. Performance was analysed using the C-statistic and the area under the receiver operating characteristic curve (AUROC). Internal validation was carried out using a 100-sample bootstrapping procedure. ORs were transformed into score items, and the AUROC was used to determine performance., Results: A total of 1459 patients who had completed 1 year of follow-up were included in the development cohort (mean age, 49±13 years; 90% women). Twenty-five (1.7%) had experienced ≥1 severe infection. According to the adjusted multivariate model, severe infection could be predicted from four variables: age (years) ≥60, previous SLE-related hospitalisation, previous serious infection and glucocorticoid dose. A score was built from the best model, taking values from 0 to 17. The AUROC was 0.861 (0.777-0.946). The cut-off chosen was ≥6, which exhibited an accuracy of 85.9% and a positive likelihood ratio of 5.48., Conclusions: SLESIS-R is an accurate and feasible instrument for predicting infections in patients with SLE. SLESIS-R could help to make informed decisions on the use of immunosuppressants and the implementation of preventive measures., Competing Interests: Competing interests: None declared., (© Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.)
- Published
- 2024
- Full Text
- View/download PDF
72. Full characterization of the three pathways of the complement system in patients with systemic lupus erythematosus.
- Author
-
García-González M, Gómez-Bernal F, Quevedo-Abeledo JC, Fernández-Cladera Y, González-Rivero AF, de Vera-González A, de la Rua-Figueroa I, López-Mejias R, Díaz-González F, González-Gay MÁ, and Ferraz-Amaro I
- Subjects
- Humans, Autoantibodies, Antibodies, Antiphospholipid, Antibodies, Antinuclear, Complement System Proteins, Lupus Erythematosus, Systemic
- Abstract
Background: To date a complete characterization of the components of the complement (C) pathways (CLassical, LEctin and ALternative) in patients with systemic lupus erythematosus (SLE) has not been performed. We aimed to assess the function of these three C cascades through functional assays and the measurement of individual C proteins. We then studied how they relate to clinical characteristics., Methods: New generation functional assays of the three pathways of the C system were assessed in 284 patients with SLE. Linear regression analysis was performed to study the relationship between the activity, severity, and damage of the disease and C system., Results: Lower values of the functional tests AL and LE were more frequent than those of the CL pathway. Clinical activity was not related to inferior values of C routes functional assays. The presence of increased DNA binding was negatively linked to all three C pathways and products, except for C1-inh and C3a which were positively related. Disease damage revealed a consistent positive, rather than a negative, relationship with pathways and C elements. Anti-ribosomes and anti-nucleosomes were the autoantibodies that showed a greater relationship with C activation, mainly due to the LE and CL pathways. Regarding antiphospholipid antibodies, the most related with C activation were IgG anti-β2GP, predominantly involving the AL pathway., Conclusion: Not only the CL route, but also the AL and LE are related to SLE features. C expression patterns are linked to disease profiles. While accrual damage was associated with higher functional tests of C pathways, anti-DNA, anti-ribosomes and anti-nucleosomes antibodies, were the ones that showed a higher relationship with C activation, mainly due to the LE and CL pathways., Competing Interests: Author IF-A received grants/research supports from Abbott, MSD, Janssen, and Roche, as well as consultation fees from company sponsored speakers bureaus associated with Abbott, Pfizer, Roche, Sanofi, Celgene, and MSD. Author MAG-G has received grants/research supports from AbbVie, MSD, Janssen, and Roche, as well as consultation fees/participation from company sponsored speakers bureaus tied to AbbVie, Pfizer, Roche, Sanofi, Lilly, Celgene, and MSD. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2023 García-González, Gómez-Bernal, Quevedo-Abeledo, Fernández-Cladera, González-Rivero, de Vera-González, de la Rua-Figueroa, López-Mejias, Díaz-González, González-Gay and Ferraz-Amaro.)
- Published
- 2023
- Full Text
- View/download PDF
73. Definition of low disease activity state based on the SLE-DAS: derivation and validation in a multicentre real-life cohort.
- Author
-
Assunção H, Jesus D, Larosa M, Henriques C, Matos A, Le Guern V, Rubiño F, da Silva JAP, Rua-Figueroa I, Costedoat-Chalumeau N, Doria A, and Inês LS
- Subjects
- Cohort Studies, Humans, Prednisone, Severity of Illness Index, Spain, Lupus Erythematosus, Systemic diagnosis, Lupus Erythematosus, Systemic drug therapy
- Abstract
Objectives: To derive and validate a definition of low disease activity (LDA) for SLE based on the SLE Disease Activity Score (SLE-DAS), in a real-life multicentre cohort of SLE patients., Methods: Derivation was conducted using data from a monocentric cohort of SLE (Portugal), and validation was performed in a multicentre cohort (Italy, France and Spain). The Lupus Low Disease Activity State (LLDAS) was used as comparator. We applied receiver operating characteristics curve analysis against the LLDAS to determine the cut-off of SLE-DAS for LDA using bootstrap methodology. In a second step, we tested a definition of SLE-DAS LDA that included: (i) the statistically derived SLE-DAS upper threshold for LDA and (ii) prednisone dose ≤7.5 mg/day. In the multicentre validation cohort, we assessed the classification performance of this SLE-DAS LDA definition., Results: We included 774 patients, 300 in the derivation and 474 in the validation cohort. In the derivation cohort, the optimal cut-off to identify patients in LLDAS was SLE-DAS ≤2.48, presenting an area under the curve of 0.965 (95% CI 0.935, 0.994). When applied to the multicentre validation cohort, the SLE-DAS LDA definition showed a sensitivity of 97.1% and a specificity of 97.7% for LLDAS and an almost perfect agreement (Cohen's Kappa = 0.933; P < 0.001). McNemar's test found no significant differences between the two definitions (P = 0.092)., Conclusion: The SLE-DAS LDA is a validated, accurate and easy-to-use definition for classifying SLE patients in LDA state., (© The Author(s) 2021. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For permissions, please email: journals.permissions@oup.com.)
- Published
- 2022
- Full Text
- View/download PDF
74. Role of targeted therapies in rheumatic patients on COVID-19 outcomes: results from the COVIDSER study.
- Author
-
Álvaro Gracia JM, Sanchez-Piedra C, Manero J, Ruiz-Lucea ME, López-Vives L, Bohorquez C, Martinez-Barrio J, Bonilla G, Vela P, García-Villanueva MJ, Navío-Marco MT, Pavía M, Galindo M, Erausquin C, Gonzalez-Gay MA, Rua-Figueroa I, Pego-Reigosa JM, Castrejon I, Sanchez-Costa JT, González-Dávila E, and Diaz-Gonzalez F
- Subjects
- Humans, Male, SARS-CoV-2, Sociodemographic Factors, Antirheumatic Agents adverse effects, COVID-19, Rheumatic Diseases drug therapy, Rheumatic Diseases epidemiology
- Abstract
Objectives: To analyse the effect of targeted therapies, either biological (b) disease-modifying antirheumatic drugs (DMARDs), targeted synthetic (ts) DMARDs and other factors (demographics, comorbidities or COVID-19 symptoms) on the risk of COVID-19 related hospitalisation in patients with inflammatory rheumatic diseases., Methods: The COVIDSER study is an observational cohort including 7782 patients with inflammatory rheumatic diseases. Multivariable logistic regression was used to estimate ORs and 95% CIs of hospitalisation. Antirheumatic medication taken immediately prior to infection, demographic characteristics, rheumatic disease diagnosis, comorbidities and COVID-19 symptoms were analysed., Results: A total of 426 cases of symptomatic COVID-19 from 1 March 2020 to 13 April 2021 were included in the analyses: 106 (24.9%) were hospitalised and 19 (4.4%) died. In multivariate-adjusted models, bDMARDs and tsDMARDs in combination were not associated with hospitalisation compared with conventional synthetic DMARDs (OR 0.55, 95% CI 0.24 to 1.25 of b/tsDMARDs, p=0.15). Tumour necrosis factor inhibitors (TNF-i) were associated with a reduced likelihood of hospitalisation (OR 0.32, 95% CI 0.12 to 0.82, p=0.018), whereas rituximab showed a tendency to an increased risk of hospitalisation (OR 4.85, 95% CI 0.86 to 27.2). Glucocorticoid use was not associated with hospitalisation (OR 1.69, 95% CI 0.81 to 3.55). A mix of sociodemographic factors, comorbidities and COVID-19 symptoms contribute to patients' hospitalisation., Conclusions: The use of targeted therapies as a group is not associated with COVID-19 severity, except for rituximab, which shows a trend towards an increased risk of hospitalisation, while TNF-i was associated with decreased odds of hospitalisation in patients with rheumatic disease. Other factors like age, male gender, comorbidities and COVID-19 symptoms do play a role., Competing Interests: Competing interests: LL-V declares the following conflicts of interest for payment or honoraria for lectures, speakers’ bureaus for Lilly. JMAG declares consulting/lecture/speaker’s bureau fees from Abbvie, BMS, Galapagos, Lilly, MSD, Pfizer, Roche and UCB. JMP-R reports the following conflicts of interest for payment or honoraria for lectures, presentations, speakers’ bureaus, manuscript writing or educational events from Janssen and Roche. MAG-G received grants/research support from AbbVie, MSD, Janssen and Roche and had consultation fees/participation in company sponsored speaker's bureau from AbbVie, Pfizer, Roche, Celgene, MSD, Novartis, SOBI and Sanofi. FD-G reports the following conflicts of interest for payment or honoraria for lectures, presentations, speakers’ bureaus for Lilly, Pfizer, UCB and Novartis; payment for expert testimony for Abbvie, Roche and MSD; support for attending meetings for Pfizer; participation on advisory board for Gilead and Receipt of equipment Abbvie. CE declares support for attending meetings and/or travel from Pfizer and UCB. PV reports receiving consulting fees from Lilly, Novartis and Fresenius Kabi; payment or honoraria for lectures, presentations, speakers’ bureaus, manuscript writing or educational events from Sandoz, BMS, GSK, Sanofi and Roche; support for attending meetings and/or travel from Abbvie, Pfizer and Roche and grants or contracts from any entity for her hospital from Abbvie, Roche and MSD. JM-B reports the following conflicts of interest for payment or honoraria for lectures, presentations, speakers’ bureaus for UCB, GSK, Lilly and Novartis; support for attending meetings for UCB, GSK and Pfizer; participation on advisory board for UCB and GSK. MG declares the following conflicts of interest for payment or honoraria for lectures, presentations, speakers’ bureaus for UCB, GSK, Lilly and Abbvie; payment for expert testimony for GSK and participation on advisory board for GSK, Abbvie and UCB., (© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.)
- Published
- 2021
- Full Text
- View/download PDF
75. Hydroxychloroquine is associated with a lower risk of polyautoimmunity: data from the RELESSER Registry.
- Author
-
Mena-Vázquez N, Fernández-Nebro A, Pego-Reigosa JM, Galindo M, Melissa-Anzola A, Uriarte-Isacelay E, Olivé-Marqués A, Aurrecoechea E, Freire M, Tomero E, García-Villanueva MJ, Stoye C, Salas-Heredia E, Bernal-Vidal JA, Salgado E, Blanco R, Javier Novoa F, Ibáñez-Barcelo M, Torrente-Segarra V, Narvaez J, Calvet J, Moriano Morales C, Ramon Vazquez-Rodriguez T, Garcia de la Peña P, Bohórquez C, Andreu-Sánchez JL, Cobo-Ibañez T, Bonilla G, Lozano-Rivas N, Montilla C, Toyos FJ, De la Fuente JLM, Expósito L, Ruiz-Lucea ME, Vals E, Manero-Ruiz J, Bernal-Vidal JA, and Rua-Figueroa I
- Subjects
- Adult, Antirheumatic Agents administration & dosage, Autoimmune Diseases immunology, Cross-Sectional Studies, Female, Humans, Hydroxychloroquine administration & dosage, Lupus Erythematosus, Systemic immunology, Male, Middle Aged, Registries, Young Adult, Antirheumatic Agents therapeutic use, Autoimmune Diseases complications, Autoimmunity drug effects, Hydroxychloroquine therapeutic use, Lupus Erythematosus, Systemic complications, Lupus Erythematosus, Systemic drug therapy
- Abstract
Objectives: This article estimates the frequency of polyautoimmunity and associated factors in a large retrospective cohort of patients with SLE., Methods: RELESSER (Spanish Society of Rheumatology Lupus Registry) is a nationwide multicentre, hospital-based registry of SLE patients. This is a cross-sectional study. The main variable was polyautoimmunity, which was defined as the co-occurrence of SLE and another autoimmune disease, such as autoimmune thyroiditis, RA, scleroderma, inflammatory myopathy and MCTD. We also recorded the presence of multiple autoimmune syndrome, secondary SS, secondary APS and a family history of autoimmune disease. Multiple logistic regression analysis was performed to investigate possible risk factors for polyautoimmunity., Results: Of the 3679 patients who fulfilled the criteria for SLE, 502 (13.6%) had polyautoimmunity. The most frequent types were autoimmune thyroiditis (7.9%), other systemic autoimmune diseases (6.2%), secondary SS (14.1%) and secondary APS (13.7%). Multiple autoimmune syndrome accounted for 10.2% of all cases of polyautoimmunity. A family history was recorded in 11.8%. According to the multivariate analysis, the factors associated with polyautoimmunity were female sex [odds ratio (95% CI), 1.72 (1.07, 2.72)], RP [1.63 (1.29, 2.05)], interstitial lung disease [3.35 (1.84, 6.01)], Jaccoud arthropathy [1.92 (1.40, 2.63)], anti-Ro/SSA and/or anti-La/SSB autoantibodies [2.03 (1.55, 2.67)], anti-RNP antibodies [1.48 (1.16, 1.90)], MTX [1.67 (1.26, 2.18)] and antimalarial drugs [0.50 (0.38, 0.67)]., Conclusion: Patients with SLE frequently present polyautoimmunity. We observed clinical and analytical characteristics associated with polyautoimmunity. Our finding that antimalarial drugs protected against polyautoimmunity should be verified in future studies., (© The Author(s) 2019. Published by Oxford University Press on behalf of the British Society for Rheumatology.)
- Published
- 2020
- Full Text
- View/download PDF
76. Can we validate a clinical score to predict the risk of severe infection in patients with systemic lupus erythematosus? A longitudinal retrospective study in a British Cohort.
- Author
-
Tejera Segura B, Rua-Figueroa I, Pego-Reigosa JM, Del Campo V, Wincup C, Isenberg D, and Rahman A
- Subjects
- Adult, Female, Hospitalization statistics & numerical data, Humans, London epidemiology, Longitudinal Studies, Male, Predictive Value of Tests, Prognosis, Reproducibility of Results, Research Design, Risk Factors, Severity of Illness Index, Infections etiology, Infections mortality, Infections therapy, Lupus Erythematosus, Systemic complications, Lupus Erythematosus, Systemic epidemiology, Risk Assessment methods
- Abstract
Objective: Severe infections are a major cause of morbidity and mortality in patients with systemic lupus erythematosus (SLE). Our primary objective was to use data from a large Spanish cohort to develop a risk score for severe infection in SLE, the SLE Severe Infection Score (SLESIS) and to validate SLESIS in a separate cohort of 699 British patients., Design and Setting: Retrospective longitudinal study in a specialist tertiary care clinic in London, UK., Participants: Patients fulfilling international classification criteria for SLE (n=209). This included 98 patients who had suffered severe infections (defined as infection leading to hospitalisation and/or death) and 111 randomly selected patients who had never suffered severe infections., Outcomes: We retrospectively calculated SLESIS at diagnosis for all 209 patients. For the infection cases we also calculated SLESIS just prior to infection and compared it to SLESIS in 98 controls matched for disease duration. We carried out receiver operator characteristic (ROC) analysis to quantify predictive value of SLESIS for severe infection., Results: Median SLESIS (IQR) at diagnosis was higher in the infection group than in the control group (4.27 (3.18) vs 2.55 (3.79), p=0.0008). Median SLESIS prior to infection was higher than at diagnosis (6.64 vs 4.27, p<0.001). In ROC analysis, predictive value of SLESIS just before the infection (area under the curve (AUC)=0.79) was higher than that of SLESIS at diagnosis (AUC=0.63)., Conclusions: We validated the association of SLESIS with severe infection in an independent cohort. Calculation of SLESIS at each clinic visit may help in management of infection risk in patients with SLE. Prospective studies are needed to confirm these findings., Competing Interests: Competing interests: None declared., (© Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.)
- Published
- 2019
- Full Text
- View/download PDF
77. Association of the microsatellite in the 3' untranslated region of the CD154 gene with rheumatoid arthritis in females from a Spanish cohort: a case-control study.
- Author
-
Martin-Donaire T, Losada-Fernandez I, Perez-Chacon G, Rua-Figueroa I, Erausquin C, Naranjo-Hernandez A, Rosado S, Sanchez F, Garcia-Saavedra A, Citores MJ, Vargas JA, and Perez-Aciego P
- Subjects
- Adult, Arthritis, Rheumatoid epidemiology, Case-Control Studies, Cohort Studies, Female, Humans, Male, Middle Aged, Spain epidemiology, 3' Untranslated Regions genetics, Alleles, Arthritis, Rheumatoid genetics, CD40 Ligand genetics, Microsatellite Repeats genetics
- Abstract
CD40-CD154 interaction is an important mediator of inflammation and has been implicated in T helper type 1-mediated autoimmune diseases including rheumatoid arthritis (RA). Linkage studies have shown association of markers in the proximity of the CD154 gene. In the present work we investigated whether specific allele variants of the microsatellite in the 3' UTR of the CD154 gene might modulate the risk of RA. The study, in a case-control setting, included 189 patients and 150 healthy controls from the Canary Islands, Spain. The 24CAs allele was less represented in female patients than in controls (0.444 in controls versus 0.307 in patients, P = 0.006, odds ratio (OR) 0.556, 95% confidence interval (CI) 0.372 to 0.831) but not in males (0.414 versus 0.408), and only when homozygous (P = 0.012; OR 0.35, 95% CI 0.16 to 0.77). We also verified that CD154 association with RA was independent of human leukocyte antigen (HLA) phenotype. A further functional study showed that after stimulation anti-CD3, CD154 mRNA was more stable in CD4+ T lymphocytes from patients with RA bearing the 24CAs allele (mRNA half-life 208 minutes) than in patients without the 24CAs allele (109 minutes, P = 0.009). However, a lower percentage of CD154+CD4+ T lymphocytes was seen in freshly isolated peripheral blood mononuclear cells from patients carrying 24CAs alleles (mean 4.28 versus 8.12; P = 0.033), and also in CD4+ T lymphocytes stimulated with anti-CD3 (median 29.40 versus 47.60; P = 0.025). These results were concordant with the smaller amounts of CD154 mRNA isolated from stimulated T lymphocytes with 24CAs alleles. The CD154 microsatellite therefore seems to affect the expression of the gene in a complex manner that implies not only mRNA stability. These data suggest that the CD154 microsatellite contributes to the regulation of mRNA and protein expression, although further studies will be necessary to elucidate its role in disease predisposition.
- Published
- 2007
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.